
    
      Using two different doses of SBRT, this study will examine the 6-month local disease control
      rate (LDCR) of the SBRT-treated metastasis to determine the optimum dosing for SBRT in
      pulmonary metastases. This will allow us to establish baseline SBRT data, from which we will
      develop a second trial to examine sequencing of immunotherapy with SBRT.
    
  